Alvimopan

Drug Profile

Alvimopan

Alternative Names: ADL 8-2698; ADL2698; Entereg; Entrareg; LY 246736; SB 767905

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Adolor Corporation; Merck & Co
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Piperidines; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postoperative ileus
  • Discontinued Constipation; Irritable bowel syndrome

Most Recent Events

  • 13 Apr 2016 Merck Sharp & Dohme and University Hospital Case Medical Center plan a phase III trial for Postoperative ileus in USA (PO) (NCT02742181)
  • 01 Jul 2015 Cubist Pharmaceuticals initiates enrolment in a phase II trial for Postoperative ileus in USA (NCT02379858)
  • 18 Mar 2015 Cubist Pharmaceuticals plans a phase II trial for Postoperative ileus in USA (NCT02379858).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top